- Home
- Publications
- Publication Search
- Publication Details
Title
Pimavanserin for the treatment of Parkinson's disease psychosis
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 14, Pages 1969-1975
Publisher
Informa Healthcare
Online
2013-09-11
DOI
10.1517/14656566.2013.819345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on Typical and Atypical Antipsychotic Drugs
- (2012) Herbert Y. Meltzer Annual Review of Medicine
- Psychiatric syndromes in Parkinsonʼs disease
- (2012) Sergio E. Starkstein et al. CURRENT OPINION IN PSYCHIATRY
- Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia
- (2012) H. Y. Meltzer et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease
- (2011) Krista McFarland et al. BEHAVIOURAL PHARMACOLOGY
- Inverse agonism and its therapeutic significance
- (2011) Gurudas Khilnani et al. INDIAN JOURNAL OF PHARMACOLOGY
- Parkinson's disease: The quintessential neuropsychiatric disorder
- (2011) Daniel Weintraub et al. MOVEMENT DISORDERS
- Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers
- (2011) Sonia Ancoli-Israel et al. SLEEP MEDICINE
- A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
- (2010) Paul Shotbolt Neuropsychiatric Disease and Treatment
- QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY
- (2009) HUBERT H. FERNANDEZ et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Epidemiology of psychosis in Parkinson's disease
- (2009) Gilles Fénelon et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania
- (2009) C.L. Dotchin et al. PARKINSONISM & RELATED DISORDERS
- 5-HT2A Inverse-Agonists for the Treatment of Insomnia
- (2008) Bradley Teegarden et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
- (2008) Atheir Abbas et al. EXPERT OPINION ON PHARMACOTHERAPY
- A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
- (2008) K VANOVER et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started